Cargando…

Time-Limited Therapy with Belatacept in Kidney Transplant Recipients

Introduction: In kidney transplant recipients, belatacept is usually pursued indefinitely after it has been started. In the setting of the belatacept shortage and after having evaluated the benefit–risk ratio, we established a strategy consisting of time-limited belatacept therapy/transient calcineu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Letellier, Thibault, Kervella, Delphine, Sadek, Abderrahmane, Masset, Christophe, Garandeau, Claire, Fourgeux, Cynthia, Gourain, Victor, Poschmann, Jeremie, Blancho, Gilles, Ville, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181670/ https://www.ncbi.nlm.nih.gov/pubmed/35683619 http://dx.doi.org/10.3390/jcm11113229

Ejemplares similares

Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients
por: Masset, Christophe, et al.
Publicado: (2023)

COVID-19 Severity in Kidney Transplant Recipients According to Their Postvaccination Serological Assessment
por: Masset, Christophe, et al.
Publicado: (2022)

A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response
por: Masset, Christophe, et al.
Publicado: (2021)

Observations on improving COVID-19 vaccination responses in kidney transplant recipients: heterologous vaccination and immunosuppression modulation
por: Masset, Christophe, et al.
Publicado: (2022)

A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients
por: Masset, Christophe, et al.
Publicado: (2022)

Sterile Pancreas Inflammation during Preservation and after Transplantation
por: Kervella, Delphine, et al.
Publicado: (2023)

Relapse of IgG4-related nephritis following mRNA COVID-19 vaccine
por: Masset, Christophe, et al.
Publicado: (2021)

Early and late ANCA vasculitis relapses after kidney transplantation may have different presentations
por: Masset, Christophe, et al.
Publicado: (2022)

Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression Modulation
por: Masset, Christophe, et al.
Publicado: (2022)

Protection of transplants against antibody-mediated injuries: from xenotransplantation to allogeneic transplantation, mechanisms and therapeutic insights
por: Kervella, Delphine, et al.
Publicado: (2022)

Collapsing glomerulopathy in a patient with APOL1 intermediate-risk genotype triggered by lupus nephritis and SARS-CoV-2 infection: lessons for the clinical nephrologist
por: Masset, Christophe, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

Incidence, Risk Factors and Outcomes of Kidney and Liver Cyst Infection in Kidney Transplant Recipient With ADPKD
por: Ronsin, Charles, et al.
Publicado: (2022)

Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly
por: Vincenti, F., et al.
Publicado: (2017)

Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept
por: Chavarot, Nathalie, et al.
Publicado: (2021)

De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019)

Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients
por: El Sakhawi, Karim, et al.
Publicado: (2020)

Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept
por: Schwarz, Chloë, et al.
Publicado: (2023)

MHC Class I Masking to Prevent AMR in a Porcine Kidney Transplantation Model in Alloimmunized Recipients
por: Kervella, Delphine, et al.
Publicado: (2023)

Belatacept conversion in African American kidney transplant recipients with severe renal dysfunction
por: Snyder, Heather S, et al.
Publicado: (2016)

Optimization of de novo belatacept‐based immunosuppression administered to renal transplant recipients
por: Kirk, Allan D., et al.
Publicado: (2020)

Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
por: Tawhari, Ibrahim, et al.
Publicado: (2022)

CD4(+) and CD8(+) regulatory T cell characterization in the rat using a unique transgenic Foxp3-EGFP model
por: Ménoret, Séverine, et al.
Publicado: (2023)

Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
por: Coscia, Lisa, et al.
Publicado: (2023)

Phase I study of single‐dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients
por: Moudgil, Asha, et al.
Publicado: (2019)

Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014)

Belatacept in renal transplantation—quo vadis?
por: Westhoff, Timm H.
Publicado: (2016)

Pilot Analysis of Late Conversion to Belatacept in Kidney Transplant Recipients for Biopsy-Proven Chronic Tacrolimus Toxicity
por: Gupta, Shruti, et al.
Publicado: (2018)

Belatacept associated - cytomegalovirus retinitis in a kidney transplant recipient: a case report and review of the literature
por: Deliège, Pierre-Guillaume, et al.
Publicado: (2020)

Belatacept Conversion in Kidney After Liver Transplantation
por: Cristea, Octav, et al.
Publicado: (2021)

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study
por: Bremer, Sara, et al.
Publicado: (2009)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

2702. A Case Series of Kidney Transplant Recipients on Belatacept with CMV Infection in a Single Academic Center
por: Feller, Fionna, et al.
Publicado: (2023)

Belatacept: Good, but not good enough?
por: Parameswaran, Sreejith, et al.
Publicado: (2012)

Belatacept: the challenges with transformational drugs
por: Vincenti, Flavio
Publicado: (2017)

Belatacept and mediastinal histoplasmosis in a kidney transplant patient
por: Trimarchi, Hernán, et al.
Publicado: (2016)

Belatacept in kidney transplant patients with systemic lupus erythematosus
por: Carrión-Barberà, Irene, et al.
Publicado: (2019)

Immune Response Post–SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept
por: Noble, Johan, et al.
Publicado: (2021)

Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients
por: Gouin, Anna, et al.
Publicado: (2020)

A cluster of broadly neutralizing IgG against BK polyomavirus in a repertoire dominated by IgM
por: Nguyen, Ngoc-Khanh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i9qjulvjb1ludoend2569s3jtj